Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. Blogs
  3. NEW Guidance on the Presentation of Disease Burden in Advertising
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

NEW Guidance on the Presentation of Disease Burden in Advertising

Scheduled Pinned Locked Moved Blogs
externalguidance documentdisease burdendisease info
1 Posts 1 Posters 454 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    Hello @manufacturer and @agency

    PAAB is pleased to announce that we have broadened our approach to disease burden presentations within advertising. The new guidance can be found under the Resources tab on the PAAB website or by following this link to the Guidance on the Presentation of Disease Burden in Advertising.

    PAAB will start accepting submissions under the new guidance as of February 19th, 2024 to allow a 6 week window for all organizations to familiarize themselves with this document prior to launch. You will also find a Case Examples document which has been designed to provide additional rationale and context for application.

    Thank you to the 15+ agencies and manufacturers who provided feedback on the development of this revised approach.

    PAAB would also like to thank bMod, CORE Health Communications, FCB Health Canada and GSW for their invaluable assistance in developing examples for this guidance.

    1 Reply Last reply
    1
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups